Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- UT Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
UTHR 
United Therapeutics Corporation (UTHR)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/31/2024: UTHR (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 36.49% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/31/2024 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 15.75B USD | Price to earnings Ratio 15.5 | 1Y Target Price 393.74 |
Price to earnings Ratio 15.5 | 1Y Target Price 393.74 | ||
Volume (30-day avg) 295856 | Beta 0.56 | 52 Weeks Range 208.62 - 417.81 | Updated Date 01/1/2025 |
52 Weeks Range 208.62 - 417.81 | Updated Date 01/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 22.76 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 40.31% | Operating Margin (TTM) 54.51% |
Management Effectiveness
Return on Assets (TTM) 11.89% | Return on Equity (TTM) 18.81% |
Valuation
Trailing PE 15.5 | Forward PE 12.66 | Enterprise Value 12825872083 | Price to Sales(TTM) 5.72 |
Enterprise Value 12825872083 | Price to Sales(TTM) 5.72 | ||
Enterprise Value to Revenue 4.65 | Enterprise Value to EBITDA 8.25 | Shares Outstanding 44644500 | Shares Floating 40925631 |
Shares Outstanding 44644500 | Shares Floating 40925631 | ||
Percent Insiders 1.85 | Percent Institutions 100.13 |
AI Summary
United Therapeutics Corporation (UTHR): A Comprehensive Overview
Company Profile:
History:
United Therapeutics Corporation (UTHR) was founded in 1996 by Martine Rothblatt, a visionary entrepreneur and lawyer, with the mission to discover and develop innovative therapies for chronic and life-threatening diseases. The company's first product, Remodulin, was approved in 2002 for the treatment of pulmonary arterial hypertension (PAH). Since then, UTHR has become a leader in the PAH field, developing and commercializing a range of innovative treatments.
Business Areas:
UTHR's core business area is the development and commercialization of therapies for PAH, a rare and fatal disease affecting the blood vessels in the lungs. The company also has a growing presence in the areas of oncology and chronic kidney disease.
Leadership & Structure:
The company is led by Dr. Martine Rothblatt, the founder and CEO. UTHR has a strong leadership team with extensive experience in the pharmaceutical industry. The company operates in a decentralized structure, with various departments responsible for different aspects of the business.
Top Products & Market Share:
- Remodulin: An inhaled vasodilator for the treatment of PAH. Remodulin is the company's flagship product and holds a significant market share in the US and globally.
- Tyvaso: An inhaled treprostinil for PAH marketed in partnership with Gilead Sciences.
- Orenitram: An oral prostacyclin for PAH. Orenitram is another key product with a growing market share.
- Unituxin: A monoclonal antibody for the treatment of chronic kidney disease.
Total Addressable Market:
The global market for PAH treatments is estimated to be around $5 billion. UTHR is a major player in this market, with its products generating significant revenue.
Financial Performance:
UTHR has been consistently profitable over the past few years. In 2022, the company reported revenue of $1.7 billion and net income of $464 million. The company's financial performance is expected to remain strong in the coming years.
Dividends & Shareholder Returns:
UTHR does not currently pay dividends. However, the company has a strong track record of share price appreciation. Over the past 5 years, UTHR's stock price has increased by over 100%.
Growth Trajectory:
UTHR has a strong growth trajectory, driven by the increasing demand for PAH treatments and the launch of new products. The company is expected to continue to grow its revenue and earnings in the coming years.
Market Dynamics:
The PAH market is expected to grow steadily in the coming years due to the increasing prevalence of the disease and the availability of new treatment options. UTHR is well-positioned to benefit from this growth.
Competitors:
- Actelion Pharmaceuticals (ATLN)
- Gilead Sciences (GILD)
- Bayer (BAYRY)
Challenges & Opportunities:
- Competition: UTHR faces competition from other major pharmaceutical companies developing PAH treatments.
- Innovation: The company needs to continue to innovate and develop new treatments to maintain its market share.
- Regulatory environment: The regulatory environment for PAH treatments is complex and constantly evolving.
Recent Acquisitions:
- 2021: UTHR acquired SteadyMed, a company specializing in medication adherence technology. This acquisition was strategic to improve patient outcomes and strengthen competitive advantage.
AI-Based Fundamental Rating:
Based on its financial health, market position, and future prospects, UTHR receives a strong AI-based fundamental rating of 8 out of 10.
Disclaimer:
This information is for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.
Sources:
- United Therapeutics Corporation website
- SEC filings
- Yahoo Finance
- Statista
Additional Notes:
- This is a brief overview of United Therapeutics Corporation. More detailed information can be found on the company's website.
- The AI-based fundamental rating is based on publicly available data and may not be entirely accurate.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Silver Spring, MD, United States | ||
IPO Launch date 1999-06-17 | Founder, Chairman & CEO Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1168 | Website https://www.unither.com |
Full time employees 1168 | Website https://www.unither.com | ||
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.